65609-19-0 Usage
Uses
Used in Pharmaceutical Industry:
1-(3,4-dimethoxybenzyl)urea is used as a potential candidate in drug development for its unique structural properties that may offer therapeutic benefits.
Used in Organic Synthesis:
1-(3,4-dimethoxybenzyl)urea is used as a reagent or intermediate in organic synthesis processes, facilitating the creation of a variety of chemical compounds.
Used as a Chemical Intermediate:
In the production of other chemical compounds, 1-(3,4-dimethoxybenzyl)urea serves as a valuable intermediate, contributing to the synthesis of complex molecules.
Used in Agrochemicals:
The presence of a urea group in 1-(3,4-dimethoxybenzyl)urea suggests its potential use in the agrochemical industry, possibly as a component in the development of new pesticides or fertilizers.
Used as a Bioactive Compound:
Due to its structural features, 1-(3,4-dimethoxybenzyl)urea may have bioactivity, making it a candidate for research into new bioactive compounds with potential applications in medicine or other fields.
Check Digit Verification of cas no
The CAS Registry Mumber 65609-19-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,5,6,0 and 9 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 65609-19:
(7*6)+(6*5)+(5*6)+(4*0)+(3*9)+(2*1)+(1*9)=140
140 % 10 = 0
So 65609-19-0 is a valid CAS Registry Number.
65609-19-0Relevant academic research and scientific papers
MONOSUBSTITUTED UREA DERIVATIVES AS A SELF-TANNING SUBSTANCE
-
Paragraph 0160; 0161; 0162; 0163; 0173; 0174; 0175, (2020/02/20)
The present invention relates to the use of monosubstiuted urea derivatives of the formula I as self-tanning substance, for increasing melanin synthesis, for improving melanin transport and/or improving the distribution of melanin in suprabasal layers, and to preparations comprising these urea derivatives.
Highly selective aldose reductase inhibitors. 1. 3-(Arylalkyl)-2,4,5- trioxoimidazolidine-1-acetic acids
Ishii,Kotani,Nagaki,Shibayama,Toyomaki,Okukado,Ienaga,Okamoto
, p. 1924 - 1927 (2007/10/03)
A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)IC50(AR) was > 1000 in some compounds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5- trioxoimidazolidine-1-acetic acid (NZ-314) was selected as the candidate for clinical development.
